FIELD: biochemistry.
SUBSTANCE: disclosed is an isolated IL-17-binding antibody. Invention also relates to an expression vector, compositions and methods of using IL-17-binding antibody for treating an IL-17-mediated disease.
EFFECT: invention enables to increase affinity, increase stability and improve the pharmacokinetics of binding antibodies to IL-17, as well as effectively neutralise the activity of IL-17 in vivo.
18 cl, 5 dwg, 4 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| ANTIBODIES DIRECTED AGAINST INTERLEUKIN-33 (IL-33) | 2015 |
|
RU2693084C2 |
| IL-1beta-BINDING ANTIBODIES AND FRAGMENTS THEREOF | 2006 |
|
RU2518295C2 |
| KIR3DL2 BINDING AGENTS | 2013 |
|
RU2682449C2 |
| ANTIBODY-FYNOMER CONJUGATES | 2015 |
|
RU2732226C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| ISOLATED SOLUBLE IL-20 RECEPTOR (VARIANTS) | 2000 |
|
RU2279441C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| INTERLEUKIN-13 BINDING PROTEINS | 2007 |
|
RU2472807C2 |
| ANGIOPOIETIN-2-SPECIFIC COUPLING AGENTS | 2005 |
|
RU2404992C2 |
